SCHEMBL3278658

SCHEMBL3278658

CCOC(=O)c1ncc(F)c2cc[nH]c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.48
JMJD6 Q6NYC1 1/20 0.43
KDM4E B2RXH2 4/20 0.41
POLB P06746 2/20 0.40
GABRA1 P14867 5/20 0.40
GABRG2 P18507 5/20 0.40
GABRB3 P28472 5/20 0.40
GABRA5 P31644 5/20 0.40
GABRA3 P34903 5/20 0.40
GABRA2 P47869 5/20 0.40
GABRA6 Q16445 4/20 0.40
GABRP O00591 3/20 0.40
GABRD O14764 3/20 0.40
GABRB1 P18505 3/20 0.40
GABRB2 P47870 3/20 0.40
GABRA4 P48169 3/20 0.40
GABRE P78334 3/20 0.40
GABRG1 Q8N1C3 3/20 0.40
GABRG3 Q99928 3/20 0.40
GABRQ Q9UN88 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431956 0.85 PIM3 (0.39) NUDT1KDM4EPOLBGABRA1GABRG2
SCHEMBL2628946 0.78 KDM4E (0.35) NUDT1KDM4E
SCHEMBL17788994 0.77 BTK (0.45) NUDT1JAK1
SCHEMBL12583931 0.76 NUDT1 (0.51) NUDT1KDM4EGABRA1GABRB2ALDH1A1
SCHEMBL25287087 0.75 KDM4E (0.47) NUDT1KDM4EALDH1A1HPGDNPSR1
SCHEMBL4909157 0.73 NUDT1 (0.51) NUDT1JMJD6KDM4EPOLBALDH1A1
SCHEMBL14785446 0.73 NUDT1 (0.55) NUDT1KDM4EGABRA1GABRB2ALDH1A1
SCHEMBL16382692 0.71 AXL (0.41) NUDT1KDM4EALDH1A1NPSR1
SCHEMBL3987258 0.70 NUDT1 (0.54) NUDT1KDM4EPOLBALDH1A1HPGD
SCHEMBL14040931 0.70 NUDT1 (0.54) NUDT1KDM4EALDH1A1HPGDJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691876-B2 Heterobicyclic amide compounds HOFFMANN-LA ROCHE INC. (US) 2010-04-06 US disclosed
EP-1984364-A1 HETEROBICYCLIC AMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
WO-2007090751-A1 HETEROBICYCLIC AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed
US-20070185154-A1 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi HOFFMANN-LA ROCHE INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185154-A1 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi APOB, CETP, LIPC NUDT1 1465/4885JMJD6 2042/4885KDM4E 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.